Scribd
Upload
30 views11 pages

She

The document presents the consolidated financial statements of Euro-Med Laboratories Phil., Inc. for the years ending December 31 from 2022 to 2025, detailing net sales, gross profit, operating expenses, and comprehensive income. It shows a steady increase in net profit and total assets over the years, with a notable rise in cash and cash equivalents. The statements also highlight the company's liabilities and equity, indicating a healthy financial position with increasing retained earnings and equity growth.

Uploaded by

Renelyn Filoteo
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
30 views11 pages

She

The document presents the consolidated financial statements of Euro-Med Laboratories Phil., Inc. for the years ending December 31 from 2022 to 2025, detailing net sales, gross profit, operating expenses, and comprehensive income. It shows a steady increase in net profit and total assets over the years, with a notable rise in cash and cash equivalents. The statements also highlight the company's liabilities and equity, indicating a healthy financial position with increasing retained earnings and equity growth.

Uploaded by

Renelyn Filoteo
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as XLSX, PDF, TXT or read online on Scribd
You are on page 1/ 11

EURO-MED LABORATORIES PHIL., INC.

AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEARS ENDED (DECEMBER 31, 2022, 2023, 2024, 2025)

Prior Year Year 1 Year 2 Year 3


2022 2023 2024 2025
Net Sales 4,224,101,893 4,646,512,082 5,204,093,532 5,984,707,562
Cost of Goods Manufactured 2,710,109,009 2,973,767,733 3,252,558,458 3,710,518,688
Gross Profit 1,513,992,884 1,672,744,350 1,951,535,075 2,274,188,874

Operating Expenses
Selling and distribution Cost 700,070,628 789,907,054 884,695,900 957,553,210
General and Administrative Expenses 373,479,253 325,255,846 364,286,547 418,929,529
Other Expenses 160,143,784 46,465,121 41,632,748 29,923,538
1,233,693,665 1,161,628,021 1,290,615,196 1,406,406,277
Profit Before Tax 280,299,219 511,116,329 660,919,879 867,782,596
Provision for Income Tax 80,411,821 146,628,289 189,603,707 248,948,174
Net Profit 199,887,398 364,488,041 471,316,172 618,834,422
Other Comprehensive Income 15,271,433 15,576,862 15,888,399 16,365,051
Total Comprehensive Income 215,158,831 380,064,902 487,204,571 635,199,473
0.358418 0.36 0.375 0.38

0.292061 0.25 0.248


0.05
EURO-MED LABORATORIES PHIL., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
FOR THE YEARS ENDED (DECEMBER 31, 2022, 2023, 2024, 2025)

Prior Year Year 1 Year 2


2,021 2022 2023 2024
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents 554,504,628 615,715,526 800,430,184 1,080,580,748
Financial assets at fair value through profit or 173,387,521 190,596,989 209,656,688 230,622,357
Trade and other receivables - net 1,559,937,090 1,620,394,619 1,782,434,081 1,960,677,489
Inventories 1,264,247,250 1,536,681,659 1,659,616,192 1,808,981,649
Other current assets 358,801,259 464,178,821 510,596,703 561,656,373

Total current assets ₱ 3,910,877,748 ₱ 4,427,567,614 ₱ 4,962,733,847 ₱ 5,642,518,616

NON-CURRENT ASSETS
Property, plant and equipment - net 4,909,130,723 4,774,452,054 5,108,663,697.78 5,517,356,793.60
Intangible Assets 268,213,158 268,132,852 294,946,137 324,440,751
Right-of-use assets-net 142,776,594 186,290,475 203,056,618 221,331,713
Deferred tax assets-net 105,949,062 97,150,502 102,008,027 107,108,428
Other non-current assets 354,459,936 305,156,782 329,569,325 332,865,018

Total Non-current Assets 5,780,529,473 5,631,182,665 6,038,243,804 6,503,102,704

TOTAL ASSETS ₱ 10,058,750,279 ₱ 11,000,977,652 ₱ 12,145,621,320

LIABILITIES
CURRENT LIABILITIES
Trade and other payables 387,534,565 416,269,851 391,293,660 367,816,040
Notes Payable 2,088,399,686 2,419,803,691 2,298,813,506.45 2,183,872,831.13
Current Portion of loans payable 195,082,085 184,304,306 165,873,875.40 149,286,487.86
Trust receipts payable 194,376,366 213,294,729 198,364,097.97 184,478,611.11
Current Portion of lease liabilities 49,177,203 60,822,206 55,956,429.52 51,479,915.16
Income Tax Payable 22,796,768 31,179,344 28,996,789.92 26,967,014.63

Total Current Liabilities ₱ 2,937,366,673 ₱ 3,325,674,127 ₱ 3,139,298,359 ₱ 2,963,900,900


NON-CURRENT LIABILITIES
Loans payable, net of current portion 788,750,467 663,622,434 656,986,210 650,416,348
Lease liabilities, net of current portion 105,290,555 138,910,238 129,944,314 78,398,980
Retirement Liability 219,322,025 221,621,228 206,107,742 191,680,200

Total Non-current Liabilities ₱ 1,113,363,047 ₱ 1,024,153,900 ₱ 993,038,266 ₱ 920,495,528

Total Liablities ₱ 4,050,729,720.00 ₱ 4,349,828,027.00 ₱ 4,132,336,625.27 ₱ 3,884,396,427.76

EQUITY
Share Capital 4,112,140,540 4,112,140,540 4,523,354,594.00 4,975,690,053.40
Additional paid-in Capital 66,609,227 66,609,227 615,309,130.70 1,191,152,491.77
Other component of equity -31787721 (16,516,288) (16,598,869.44) (16,681,863.79)
Retained Earnings 1,493,715,455 1,546,688,773 1,746,576,171.00 2,111,064,211.51

Total Equity ₱ 5,640,677,501 ₱ 5,708,922,252 ₱ 6,868,641,026 ₱ 8,261,224,893

TOTAL LIABILITIES AND EQUITY ₱ 9,691,407,221 ₱ 10,058,750,279 ₱ 11,000,977,652 ₱ 12,145,621,320


Year 3
2025

1,512,813,047
253,684,592
2,156,745,238
1,989,879,814
617,822,011

₱ 6,530,944,702

6,013,918,905.03
356,884,826
241,251,568
112,463,850
336,193,668

7,060,712,816

₱ 13,591,657,519

364,137,880
2,009,163,004.64
135,850,703.95
177,099,466.67
50,965,116.01
25,079,323.60

₱ 2,762,295,495
597,537,911
70,559,082
182,096,190

₱ 850,193,183

₱ 3,612,488,677.82

5,473,259,058.74
1,940,294,671.95
(16,765,273.11)
2,582,380,383.17

₱ 9,979,168,841

₱ 13,591,657,519
1.35 1.4 0
(0.00)

271,907,749.94
3,612,488,677.81

(271,907,749.94)

0
EURO-MED LABORATORIES PHIL., INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE YEARS ENDED (DECEMBER 31, 2022, 2023, 2024, 2025)

2022 2023 2024 2025


CASH FLOWS FROM OPERATING ACTIVITIES
Profit before tax 280,299,219 511,116,329 660,919,879 867,782,596
Adjustments:
Depreciation 286,814,130 306,891,119 328,373,497 357,927,112
Interest Expense 206,795,732 208,863,689 221,395,511 241,321,107
Retirement Benefit Expense 27,866,313 28,144,976 29,552,225 32,507,447
Bad Debt Expense 4,251,415 4,293,929 4,336,868 4,640,449
Unrealized Loss (gain) on financial statements
at fair value through profit or loss 1,091,309 1,102,222 1,190,400 1,202,304
Amortization of Intangible Assets 80,306 81,109 86,787 93,730
Interest Income (503,281) (513,347) (518,480) (559,958)
Loss (gain) on lease modification (3,191,700) (3,223,617) (3,255,853) (3,516,321)
Unrealized loss (gain) on foreign exchange (21,727,963) (21,945,243) (22,164,695) (23,937,871)
Operating Profit before working capital changes 781,775,480 1,034,811,168 1,219,916,138 1,477,460,595
Decrease (increase) in:
Trade and other receivables (64,708,944) (19,059,699) (178,243,408) (196,067,749)
Inventories (272,434,409) (122,934,533) (149,365,457) (180,898,165)
Other Current Assets (105,377,562) (46,417,882) (51,059,670) (56,165,637)
Other non-current assets 50,283,027 (24,412,543) (3,295,693) (3,328,650)
Increase (decrease) in trade and other payables 28,735,286 (24,976,191) (23,477,620) (3,678,160)
Net cash generated from operations 418,272,878 797,010,320 814,474,290 1,037,322,233
Interest received 503,281 508,314 513,397 35,919,390
Retirement benefits paid (5,205,198) (5,257,250) (5,309,822) (5,362,921)
Income tax paid (68,888,764) (69,577,652) (70,273,428) (70,976,162)
Interest paid (196,448,431) (198,412,915) (200,397,044) (202,401,015)

Net Cash Provided by Operating Activities 148,233,766 524,270,817 539,007,392 794,501,525

CASH FLOWS INVESTING ACTIVITIES


Addition to property, plant and equipment (88,888,017) (334,211,644) (408,693,096) (496,562,111)
Withdrawal of financial assets at fair value
through profit or loss
Net Cash Used in Investing Activities (88,888,017) (334,211,644) (408,693,096) (496,562,111)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from availment of notes payable 2,379,994,840 2,403,794,788 2,576,395,006 2,834,034,507
Proceeds from availment of loans 64,000,000 64,640,000 70,457,600 76,094,208
Net Payments of trust receipts payable 18,918,363 18,759,494 20,447,848 22,083,676
Payment of lease liabilities (72,053,674) (75,656,358) (76,412,921) (102,229,320)
Dividends paid (143,924,919) (145,364,168) (146,817,810) (178,266,600)
Payment of loans (199,905,812) (205,902,986) (207,962,016) (244,302,343)
Payment of notes payable (2,048,590,835) (2,069,076,743) (2,089,767,511) (2,276,652,277)

Net Cash Used in Financing Activities (1,562,037) (8,805,974) 146,340,196 130,761,852

EFFECT OF EXCHANGE RATES ON CASH


AND CASH EQUIVALENTS 3,427,186 3,461,458 3,496,072 3,531,033

NET INCREASE (DECREASE)


IN CASH AND CASH EQUIVALENTS 61,210,898 184,714,658 280,150,565 432,232,299

CASH AND CASH EQUIVALENTS


AT BEGINNING OF THE YEAR 554,504,628 615,715,526 800,430,184 1,080,580,748

CASH AND CASH


EQUIVALENTS AT END OF THE YEAR ₱ 615,715,526 ₱ 800,430,184 ₱ 1,080,580,748 ₱ 1,512,813,047

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy